SSSS
MCID: RTT001
MIFTS: 40

Ritter's Disease (SSSS) malady

Categories: Skin diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Ritter's Disease

Aliases & Descriptions for Ritter's Disease:

Name: Ritter's Disease 12 14
Staphylococcal Scalded Skin Syndrome 12 56 52 42 69
Pemphigus Neonatorum 12 69
Toxic Epidermal Necrolysis, Subcorneal Type 12
Dermatitis Exfoliativa Neonatorum 12
Generalized Exfoliative Disease 56
Scalded Skin Syndrome 12
Ritter Disease 12
Ssss 56

Characteristics:

Orphanet epidemiological data:

56
staphylococcal scalded skin syndrome
Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 56  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:9063
ICD10 33 L00
ICD9CM 35 695.81
MeSH 42 D013206
NCIt 47 C85077
Orphanet 56 ORPHA36236
MESH via Orphanet 43 D013206
UMLS via Orphanet 70 C0038165
ICD10 via Orphanet 34 L00
UMLS 69 C0038165

Summaries for Ritter's Disease

Disease Ontology : 12 A commensal bacterial infectious disease that is characterized by widespread erythema, peeling, and necrosis of the skin, that is caused by a toxin produced by a bacterium of the genus Staphylococcus (S. aureus). The infection has symptoms redness of skin, has symptom fluid-filled blister formation, has symptom fever and has symptom irritability.

MalaCards based summary : Ritter's Disease, also known as staphylococcal scalded skin syndrome, is related to dermatitis and impetigo, and has symptoms including fluid-filled blister formation, fever and irritability. An important gene associated with Ritter's Disease is DSG1 (Desmoglein 1), and among its related pathways/superpathways are Keratinization and Apoptotic cleavage of cellular proteins. The drugs Yohimbine and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include skin, and related phenotype is vision/eye.

Related Diseases for Ritter's Disease

Graphical network of the top 20 diseases related to Ritter's Disease:



Diseases related to Ritter's Disease

Symptoms & Phenotypes for Ritter's Disease

Symptoms:

12
  • fluid-filled blister formation
  • fever
  • irritability

MGI Mouse Phenotypes related to Ritter's Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 8.92 DSG1 EDNRA EDNRB HSF4

Drugs & Therapeutics for Ritter's Disease

Drugs for Ritter's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Yohimbine Approved, Vet_approved Phase 4 146-48-5 8969
2
Guaifenesin Approved, Vet_approved Phase 4 93-14-1 3516
3
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
4
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
5
Adalimumab Approved Phase 4 331731-18-1 16219006
6
Etanercept Approved, Investigational Phase 4 185243-69-0
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
9
Povidone-iodine Approved Phase 4 25655-41-8
10
leucovorin Approved, Nutraceutical Phase 4,Phase 3 58-05-9 54575, 6560146 143
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
12 Analgesics Phase 4
13 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
14 Mydriatics Phase 4
15 Adrenergic Agents Phase 4,Phase 3,Phase 1
16 Adrenergic Antagonists Phase 4,Phase 3,Phase 1
17 Adrenergic alpha-Antagonists Phase 4,Phase 3
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 1
19 Peripheral Nervous System Agents Phase 4,Phase 3
20 Anti-Infective Agents Phase 4,Phase 3
21 Autonomic Agents Phase 4,Phase 3
22
Iodine Phase 4 7553-56-2 807
23 cadexomer iodine Phase 4
24 Chlorhexidine gluconate Phase 4
25 Folic Acid Antagonists Phase 4
26 Gastrointestinal Agents Phase 4
27 Nucleic Acid Synthesis Inhibitors Phase 4
28 Analgesics, Non-Narcotic Phase 4
29 Dermatologic Agents Phase 4
30 Trace Elements Phase 4
31 Disinfectants Phase 4
32 Vitamin B Complex Phase 4
33 Plasma Substitutes Phase 4
34 Povidone Phase 4
35 Immunosuppressive Agents Phase 4,Phase 3
36 Anti-Infective Agents, Local Phase 4
37 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
38 Antimalarials Phase 4
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4
40 Antimetabolites Phase 4,Phase 3,Phase 1
41 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1
42 Micronutrients Phase 4
43 Antirheumatic Agents Phase 4
44 Blood Substitutes Phase 4
45 Antiparasitic Agents Phase 4
46 Antiprotozoal Agents Phase 4
47 Yohimbe Nutraceutical Phase 4
48 Folate Nutraceutical Phase 4,Phase 3
49 Vitamin B9 Nutraceutical Phase 4,Phase 3
50
Norepinephrine Approved Phase 3 51-41-2 439260

Interventional clinical trials:

(show all 42)
id Name Status NCT ID Phase
1 Clinical Evaluation on Advanced Resynchronization Completed NCT00658203 Phase 4
2 Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine Completed NCT00975325 Phase 4
3 Treatment of Predominant Central Sleep Apnoea by Adaptive Servo Ventilation in Patients With Heart Failure Completed NCT00733343 Phase 4
4 AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft Recruiting NCT02480595 Phase 4
5 Treatments Against RA and Effect on FDG-PET/CT Recruiting NCT02374021 Phase 4
6 Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation Recruiting NCT01841242 Phase 4
7 Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography Active, not recruiting NCT01869062 Phase 4
8 Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder Completed NCT01309542 Phase 3
9 Lurasidone Extended Use Study Completed NCT01485640 Phase 3
10 Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance Completed NCT02673749 Phase 2, Phase 3
11 Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on) Completed NCT00868452 Phase 3
12 Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy) Completed NCT00868699 Phase 3
13 Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression Completed NCT00868959 Phase 3
14 Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device Completed NCT02167789 Phase 3
15 Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML Recruiting NCT02140242 Phase 3
16 Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study Recruiting NCT01657604 Phase 3
17 A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Recruiting NCT02605837 Phase 3
18 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Recruiting NCT02736409 Phase 3
19 Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy Recruiting NCT01827553 Phase 3
20 Continuous Positive Airway Pressure Ventilation After Acute Ischemic Stroke Completed NCT00151177 Phase 1, Phase 2
21 Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance Completed NCT01113619 Phase 2
22 Intensity Modulated Radiation Therapy (IMRT) Radiotherapy for Treating Prostate Pelvic Nodes Completed NCT00214136 Phase 2
23 Tepotinib Phase II in NSCLC Harbouring MET Exon 14 (METex14) Skipping Alterations Recruiting NCT02864992 Phase 2
24 Phase I/II Hypofractionated Radiotherapy for Prostate Cancer Active, not recruiting NCT00214097 Phase 1, Phase 2
25 A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus Unknown status NCT02040012 Phase 1
26 Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients Completed NCT01103609 Phase 1
27 A Study Conducted Over 3 Periods to Look at the Drug in the Body Completed NCT01225939 Phase 1
28 Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects Completed NCT01311622 Phase 1
29 Stereotactic Body Radiation Therapy and Capecitabine Before Surgery in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery Recruiting NCT01918644 Phase 1
30 A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401 Terminated NCT01627002 Phase 1
31 To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension Terminated NCT01403922 Phase 1
32 A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis Terminated NCT01975688 Phase 1
33 Randomized Comparison of Endocardial Versus Epicardial - From the Coronary Sinus - Left Ventricular Pacing for Resynchronization in Heart Failure. Unknown status NCT01260402
34 The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA) Completed NCT00822276
35 Magnesium Replacement Therapy to Prevent Acute Renal Failure in Critically Ill Patients Completed NCT01700998
36 Economic Evaluation Comparing CCT With MMT in Hai Phong City, Vietnam Completed NCT03071315
37 Sleep-Disordered Breathing in Heart Failure - The SchlaHF-Registry Completed NCT01500759
38 Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer Recruiting NCT02470897
39 Triadyme-C, a Polycrystalline Diamond Compact Cervical Disc Replacement (cTDR) Recruiting NCT02967575
40 Impact of Fever Prevention in Brain Injured Patients Recruiting NCT02996266
41 Master Study of the Ilivia ICD Family and the Plexa ICD Lead Recruiting NCT02774616
42 Smartphone-based Ambulatory Assessment of Early Warning Signs Not yet recruiting NCT02782910

Search NIH Clinical Center for Ritter's Disease

Cochrane evidence based reviews: staphylococcal scalded skin syndrome

Genetic Tests for Ritter's Disease

Anatomical Context for Ritter's Disease

MalaCards organs/tissues related to Ritter's Disease:

39
Skin

Publications for Ritter's Disease

Articles related to Ritter's Disease:

(show all 28)
id Title Authors Year
1
Picture of the month. Ritter's disease (neonatal staphylococcal scalded skin syndrome). ( 1558075 )
1992
2
Nosocomial scalded skin syndrome. Ritter's disease caused by phage group 3 Staphylococcus aureus. ( 6449146 )
1980
3
Atopic dermatitis and Ritter's disease: differential diagnosis by means of total and specific serum IgE. ( 147160 )
1978
4
Toxic epidermal necrolysis (TEN; Ritter's disease) and staphylococcal scalded skin syndrome (SSSS). A description and review. ( 780034 )
1976
5
Total and specific IgE levels as a means of differentiating Ritter's disease from atopic dermatitis. ( 127536 )
1975
6
New type of exfoliatin obtained from staphylococcal strains, belonging to phage groups other than group II, isolated from patients with impetigo and Ritter's disease. ( 4139120 )
1974
7
Epidemic boric acid poisoning simulating staphylococcal toxic epidermal necrolysis of the newborn infant: Ritter's disease. ( 4251286 )
1970
8
Haemolysin and enzyme patterns of coagulase-positive staphylococci isolated from toxic epidermal necrolysis, Ritter's disease and impetigo contagiosa. ( 4252396 )
1969
9
Toxic epidermal necrolysis (the scalded skin syndrome). Its association in two cases with pathogenic staphylococci and its similarity in infancy to Ritter's disease. ( 4222069 )
1966
10
RITTER'S DISEASE. ( 14291657 )
1965
11
Epidemic staphylococcal pyoderma associated with Ritter's disease and the appearance of phage type 3B/71. ( 13975789 )
1963
12
Ritter's disease: exfoliative dermatitis of the newborn. ( 13869919 )
1962
13
An outbreak of exfoliative dermatitis of the newborn (Ritter's disease) due to Staphylococcus aureus, phage-type 55/71. ( 13867356 )
1962
14
An outbreak of Ritter's disease. ( 13763310 )
1961
15
Some interesting but rare disorders seen in pediatric practice with case report of Ritter's disease with recovery. ( 13502281 )
1958
16
Ritter's disease (dermatitis exfoliativa neonatorum) with recovery. ( 13464996 )
1957
17
Dermatitis exfoliativa neonatorum; Ritter's disease. ( 13468377 )
1957
18
Ritter's disease with recovery. ( 13166184 )
1954
19
Ritter's disease and sclerema; report on two rare cases in infants. ( 14921951 )
1952
20
Impetigo and acute infectious exfoliative dermatitis of the newborn infant (Ritter's disease). ( 14955740 )
1952
21
Ritter's disease. ( 18120097 )
1949
22
Ritter's disease. ( 18920581 )
1948
23
Ritter's disease; report of a case treated with vitamins and penicillin with recovery. ( 18101843 )
1948
24
Topical and parenteral penicillin therapy in Ritter's disease; report of four cases with recovery. ( 18101064 )
1948
25
Ritter's disease in fraternal twins, with special reference to the pathogenesis. ( 20255863 )
1947
26
Ritter's disease (dermatitis exfoliativa neonatorum); report of a case. ( 20275913 )
1946
27
A case of exfoliative dermatitis of the newborn (Ritter's disease). ( 21032230 )
1942
28
A CASE OF RITTER'S DISEASE. ( 20770997 )
1923

Variations for Ritter's Disease

Expression for Ritter's Disease

Search GEO for disease gene expression data for Ritter's Disease.

Pathways for Ritter's Disease

Pathways related to Ritter's Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.79 DSG1 DSG2 DSG4
2
Show member pathways
11.39 DSG1 DSG2
3 10.98 EDNRA EDNRB
4 10.49 EDNRA EDNRB
5 10.1 EDNRA EDNRB

GO Terms for Ritter's Disease

Cellular components related to Ritter's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 lateral plasma membrane GO:0016328 9.16 DSG1 DSG2
2 cornified envelope GO:0001533 9.13 DSG1 DSG2 DSG4
3 desmosome GO:0030057 8.8 DSG1 DSG2 DSG4

Biological processes related to Ritter's Disease according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.67 DSG1 DSG2 DSG4
2 keratinization GO:0031424 9.54 DSG1 DSG2 DSG4
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.51 EDNRA EDNRB
4 single organismal cell-cell adhesion GO:0016337 9.48 DSG1 DSG4
5 regulation of blood pressure GO:0008217 9.46 EDNRA EDNRB
6 response to progesterone GO:0032570 9.43 DSG1 DSG2
7 homophilic cell adhesion via plasma membrane adhesion molecules GO:0007156 9.43 DSG1 DSG2 DSG4
8 maternal process involved in female pregnancy GO:0060135 9.4 DSG1 DSG2
9 vasoconstriction GO:0042310 9.32 EDNRA EDNRB
10 enteric nervous system development GO:0048484 9.16 EDNRA EDNRB
11 cornification GO:0070268 9.13 DSG1 DSG2 DSG4
12 endothelin receptor signaling pathway GO:0086100 8.62 EDNRA EDNRB

Molecular functions related to Ritter's Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.13 DSG1 DSG2 DSG4
2 endothelin receptor activity GO:0004962 8.62 EDNRA EDNRB

Sources for Ritter's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....